Clinical trial · Interventional
Definitive Therapy for Oligometastatic Solid Malignancies
A Prospective Investigation of Definitive Targeted Therapy for Solid Malignancies With Oligometastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival. In the setting of increasingly effective systemic therapy and limited metastatic disease, aggressive treatment to clinically active sites of disease (alone or in addition to systemic therapy) may improve survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage IV or Recurrent Carcinoma or Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ablative external beam radiation dose | Radiation | — | UNRESOLVED |
| Complete Surgical Removal | Procedure | — | UNRESOLVED |
| Radioembolization | Radiation | — | UNRESOLVED |
| Stereotactic Radiosurgery | Radiation | — | UNRESOLVED |
| Subtotal surgical removal plus ablative radiation dose | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Definitive locoregional treatment
- description
- All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
- interventionNames
- Procedure: Complete Surgical Removal
- Radiation: Stereotactic Radiosurgery
- Radiation: Ablative external beam radiation dose
- Procedure: Subtotal surgical removal plus ablative radiation dose
- Radiation: Radioembolization
Primary outcomes (1)
- measure
- Survival
- timeFrame
- 5 years
- description
- Overall and disease-specific survival, to be assessed at 1, 3, and 5 years.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 4 or less distinct sites of active disease. Locoregional disease counts as one site * All sites of disease can safely be encompassed by radiation fields to doses ≥ 45 Gy (biologic equivalent dose) and/or removed completely with surgery and/or completely ablated with other appropriate site-specific techniques. * sufficient blood cell counts and adequate liver function Exclusion Criteria: * Hematologic malignancies * Distinct sites of disease \> 4 * Karnofsky Performance Status \< 70 * Unexplained weight loss \> 10 % * HIV, chronic viral hepatitis, or any chronically active infection * Life expectancy \< 6 months for any reason
References
Publications (0)
Data not yet available